Category: Product

 

Shaped by Industry Leaders: Atreo’s v2.0 Launches in Partnership with Top 10 Sponsors 

San Francisco, April 22nd, 2025

Atreo, the next generation Randomization and Trial Supply Management (RTSM) provider, has released its groundbreaking v2.0 Platform. Specifically designed in collaboration with large pharmaceutical and biotech client partners, v2.0 brings unmatched RTSM configuration capabilities to sponsors and CROs. 

Atreo’s latest release represents yet another significant leap forward in RTSM solutions, offering unparalleled agility for even the most complex protocol designs through 100% configurable solutions.  These advancements underscore Atreo’s unwavering commitment to redefining the modern RTSM delivery experience and continuous RTSM innovation, bringing life-saving drugs to market faster, while ensuring a simplified site experience.  Key v2.0 highlights include: 

• Enriched User Interface: Refined UI/UX design for more intuitive workflows, prioritizing a simplified, user-friendly site experience. 

• Expansion of Configurability Options:  Numerous advancements of configurable RTSM options, further limiting custom coding for any builds and system changes. 

• Advanced Cross-Protocol Reporting:  Unprecedented program level supplies reporting, surfacing actionable insights to make data-driven decisions.  

• Refined Drug Pooling Features:  Configurable drug pooling capabilities enabling seamless program level inventory management  

“The launch of v2.0 marks a major milestone for Atreo, our client partners, and site users, reflecting our dedication to continuous innovation driving a simplified, high-quality experience for our global users,” said Ryan Harrison, Atreo CEO.  “We’re proud to provide a platform that not only addresses the unique challenges faced by large pharma but also accelerates the journey of bringing vital therapies to patients worldwide for sponsors of all sizes.  Having witnessed firsthand the downstream impact of stalled R&D efforts at companies in our field, Atreo’s leadership team remains committed to delivering future releases that continually improve client and site experiences.  Our unwavering commitment also enables Atreo to overcome the scalability challenges and limitations of outdated RTSM technology, delivering curated solutions without cumbersome SDLC models, costly delays, and quality issues common of yesterday’s options.” 

About Atreo: https://www.atreo.io

Atreo is a modern RTSM company, comprised of experienced clinical technology experts, that delivers next generation RTSM solutions.  Atreo helps clinical teams to modernize the RTSM experience with unmatched agility and simplicity. Atreo has solved all common RTSM challenges, offering numerous unmatched advantages with a specific emphasis on: 

Speed: 1 – 2 Week RTSM build from Kickoff to Launch
Collaborative RTSM Design: RTSM built before your Kickoff Meeting
Reduced Costs:  No Cost System changes delivered within days.   

 

Agile Functionality Address an Unmet Need Within Clinical Development 

SAN FRANCISCO, June 27, 2024

Atreo, Inc., a Clinical Development technology company focused on modernizing and simplifying the RTSM delivery experience, recently launched groundbreaking precision medicine RTSM capabilities in support of a leading radiopharm organization to address an unmet need within the life sciences space, offering standard functionality to address the growing emergence of targeted therapeutics.

“Atreo’s team has collaborated with several precision medicine sponsor organizations in recent months, and it became clear that an agile RTSM solution to support the nuances of their studies did not exist,” said Ryan Harrison, Atreo CEO. “Given the efficacy of targeted therapies and increasing frequency of these study designs, our team made a strategic decision to build standard RTSM functionality to support the requirements of such protocols. Rather than develop a standalone custom system to support our partner, we followed Atreo’s product methodology by embedding all precision medicine features into our core product.”

“RTSM systems have historically lacked out of the box, configurable functionality to support precision medicine, radiopharm, and cell | gene therapy trials,” said Jon Ball, Atreo COO. “Atreo’s unique functionality, built within our next generation Studio RTSM configuration platform, allows precision medicine RTSM solutions to be seamlessly delivered via 100% configuration, ensuring a quality profile that has proven historically challenging to maintain when building bespoke systems.”

Atreo’s future RTSM product releases will expand upon its personalized medicine solutions. “Precision medicine focused clinical teams have embraced the guidance of Atreo’s team on how to deliver a simplified, intuitive solution for the unique workflows of their trial designs,” said Brian Dunton, Atreo’s Head of Client Services. “We encourage all precision medicine focused sponsors to collaborate with Atreo’s team on how our RTSM solution can be leveraged to streamline their experiences.”

About Atreo (https://atreo.io)

Atreo is a Clinical Technology company, comprised of experienced Clinical Technology experts, that offers the next generation of RTSM platform. Atreo helps Clinical Teams to modernize the RTSM experience with unmatched agility and simplicity by leveraging advanced technology and testing methods. Atreo has addressed all common RTSM pain points. Our solution offers numerous advantages, with a specific emphasis on:

• Speed: 1 – 2 week RTSM build from Kickoff to Go-Live
• Quality Quantified: Modern testing practices mitigating RTSM risk
• Agility: Simplified system changes at no cost and unmatched quality

 

Atreo’s Next Generation RTSM Features on Display at Informa IRT 2024

San Francisco, CA, October 14, 2024

Atreo, Inc., a next generation Clinical Development SaaS company focused on modernizing and simplifying the RTSM delivery experience, announces the arrival of our most comprehensive product release to date, focused on expansion of Clinical Supplies management tools and enhancements to our in-platform collaboration tool, further streamlining the RTSM build and UAT experiences for Atreo’s client partners.

“As Atreo’s client portfolio continues to grow, we’ve been so fortunate to collaborate with clients and industry experts who have generously shared their expertise and invested in our ongoing refinement of our products,” said Rebecca Stone, Senior Director of Product at Atreo. “Customer feedback has always been at the core of our approach to enhancing RTSM features. Our recent v1.6 and v1.7 Studio releases were thoughtfully curated in close partnership with experienced Clinical Supplies professionals, with a focus on streamlining IP management and simplifying the RTSM experience for sites users.”

“Since joining Atreo, I’ve been incredibly impressed by the thoughtful advancements the team has integrated into our Studio platform,” said Evan Hahn, Atreo’s newly appointed Head of Global Sales. “The platform’s agility and expansive configurable options have far surpassed my lofty expectations. This is the RTSM solution I’ve been championing since entering the field 15 years ago. Our v1.7 release marks another significant step towards modernizing the RTSM experience for both Atreo’s clients and our internal teams.”

About Atreo: https://atreo.io

Atreo is a Clinical Technology company and a top destination of RTSM experts, that has created the next generation RTSM platform.  Atreo helps Clinical Teams to modernize the RTSM experience with unmatched agility and simplicity by leveraging advanced technology and testing methods. Atreo has addressed all common RTSM pain points.  Our solution offers numerous advantages, with a specific emphasis on:

Speed:  1 – 2 week RTSM build from Kickoff to Go-Live

Quality Quantified:  Modern testing practices mitigating RTSM risk

Agility:  Simplified system changes at no cost and unmatched quality